HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
23 Apr 2018 01:10 PM
RNS
Grant of Share Options under Share Option Scheme
23 Apr 2018 01:05 PM
RNS
Block Admission
29 Mar 2018 07:00 AM
RNS
Total Voting Rights
28 Mar 2018 07:00 AM
RNS
Vesting of awards under Long Term Incentive Plan
26 Mar 2018 07:00 AM
RNS
Annual Report & Notice of Annual General Meeting
21 Mar 2018 09:25 AM
RNS
Director's Share Dealing
20 Mar 2018 09:15 AM
RNS
Grant of Share Options under Share Option Scheme
19 Mar 2018 07:10 AM
RNS
Director's Share Dealing
12 Mar 2018 11:22 AM
RNS
Publication of Form 20-F
12 Mar 2018 07:02 AM
RNS
Final Results and Key Clinical Programs Update
06 Mar 2018 07:00 AM
RNS
Phase Ib/II Trial of Epitinib in Glioblastoma
13 Feb 2018 07:01 AM
RNS
Enrolment completed Ph III FALUCA Fruquintinib
05 Feb 2018 07:00 AM
RNS
Chi-Med to Announce 2017 Final Results
29 Dec 2017 07:00 AM
RNS
Block listing Interim Review
29 Dec 2017 07:00 AM
RNS
Total Voting Rights
15 Dec 2017 07:00 AM
RNS
Chi-Med Initiates Fruquintinib US Clinical Trials
01 Nov 2017 09:45 AM
RNS
Notification of Major Holdings
01 Nov 2017 09:45 AM
RNS
NOTIFICATION OF MAJOR HOLDINGS
31 Oct 2017 07:00 AM
RNS
FRUTIGA, a Phase III trial of Fruquintinib
30 Oct 2017 03:30 PM
RNS
Closing of U.S. Public Offering of ADSs
27 Oct 2017 12:10 PM
RNS
Chi-Med Announces Over-allotment Option
26 Oct 2017 07:00 AM
RNS
Chi-Med Announces Pricing Raising US$262 million
25 Oct 2017 07:00 AM
RNS
Chi-Med Announces Proposed Offering of ADSs
19 Oct 2017 09:20 AM
RNS
Notification of Major Interest in Shares
17 Oct 2017 07:00 AM
RNS
Savolitinib Shows Encouraging Clinical Activity
16 Oct 2017 07:00 AM
RNS
Chi-Med Reports Preliminary Phase II data
12 Oct 2017 07:30 AM
RNS
Appointment of Director
29 Sep 2017 07:04 AM
RNS
Savolitinib and Fruquintinib presentations at WCLC
29 Sep 2017 07:00 AM
RNS
Oral Presentations at CSCO Annual Meeting
29 Sep 2017 07:00 AM
RNS
Total Voting Rights
31 Aug 2017 10:15 AM
RNS
Director's Share Dealing
29 Aug 2017 07:00 AM
RNS
Start of HMPL 689 Phase I Trial in China
22 Aug 2017 09:00 AM
RNS
Director's Share Dealing
18 Aug 2017 10:50 AM
RNS
Directors' Share Dealing
15 Aug 2017 10:30 AM
RNS
Directors' Share Dealing
10 Aug 2017 09:35 AM
RNS
Director's Share Dealing
07 Aug 2017 09:45 AM
RNS
Directors' Share Dealing
31 Jul 2017 07:00 AM
RNS
Chi-Med Reports 2017 Interim Results
30 Jun 2017 07:00 AM
RNS
Total Voting Rights
29 Jun 2017 07:00 AM
RNS
Start of Savolitinib Global PRCC Phase III Trial
29 Jun 2017 07:00 AM
RNS
Blocklisting Six Monthly Return
29 Jun 2017 07:00 AM
RNS
Chi-Med to Announce 2017 HY Financial Results
22 Jun 2017 07:00 AM
RNS
Chi-Med starts Ph I/II Trial of HMPL 453 in China
16 Jun 2017 09:57 AM
RNS
Director's Share Dealing
12 Jun 2017 07:00 AM
RNS
Fruquintinib NDA for Advanced CRC Filed with CFDA
06 Jun 2017 07:00 AM
RNS
Phase III Fruquintinib Data presented at ASCO
18 May 2017 07:00 AM
RNS
Chi-Med Presents Clinical Data at ASCO 2017
28 Apr 2017 01:40 PM
RNS
Total Voting Rights
27 Apr 2017 02:10 PM
RNS
Results of Annual General Meeting
07 Apr 2017 07:00 AM
RNS
Pre-clinical Data Presented at AACR

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings